The Committee holds an Executive Session entitled, “Authorization for Investigation into the High Costs of Prescription Drugs and Related Subpeonas” with CEO Duato of Johnson & Johnson and CEO Davis of Merck on January 31 at 11:00 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- J&J says FDA grants full approval for Balversa for mUC with genetic alterations
- FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
- Johnson & Johnson reports regulatory approval of Varipulse PFA platform in Japan
- Ambrx Biopharma downgraded to Market Perform from Outperform at JMP Securities
- M & A News: Johnson & Johnson (NYSE:JNJ) to Acquire Ambrx Biopharma
